Annual Accounts Payable
$2.11 B
-$193.49 M-8.39%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual accounts payable is $2.11 billion, with the most recent change of -$193.49 million (-8.39%) on March 31, 2024.
- During the last 3 years, TAK annual accounts payable has risen by +$9.91 million (+0.47%).
- TAK annual accounts payable is now -12.81% below its all-time high of $2.42 billion, reached on March 31, 2022.
Performance
TAK Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.93 B
+$36.26 M+1.25%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly accounts payable is $2.93 billion, with the most recent change of +$36.26 million (+1.25%) on December 1, 2024.
- Over the past year, TAK quarterly accounts payable has increased by +$36.26 million (+1.25%).
- TAK quarterly accounts payable is now -14.56% below its all-time high of $3.43 billion, reached on December 31, 2023.
Performance
TAK Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
TAK Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -8.4% | +1.3% |
| 3 y3 years | +0.5% | +27.0% |
| 5 y5 years | +10.4% | +39.3% |
TAK Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -12.8% | +0.5% | -14.6% | +38.6% |
| 5 y | 5-year | -12.8% | +10.4% | -14.6% | +49.6% |
| alltime | all time | -12.8% | +395.4% | -14.6% | +265.2% |
Takeda Pharmaceutical Company Limited Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $2.93 B(+1.3%) |
| Sep 2024 | - | $2.89 B(-0.7%) |
| Jun 2024 | - | $2.91 B(+37.8%) |
| Mar 2024 | $2.11 B(-8.4%) | $2.11 B(-38.4%) |
| Dec 2023 | - | $3.43 B(+21.7%) |
| Sep 2023 | - | $2.82 B(-7.4%) |
| Jun 2023 | - | $3.05 B(+32.0%) |
| Mar 2023 | $2.31 B(-4.8%) | $2.31 B(-20.6%) |
| Dec 2022 | - | $2.91 B(+8.1%) |
| Sep 2022 | - | $2.69 B(-13.4%) |
| Jun 2022 | - | $3.11 B(+28.1%) |
| Mar 2022 | $2.42 B(+15.2%) | $2.42 B(-20.6%) |
| Dec 2021 | - | $3.05 B(+1.5%) |
| Sep 2021 | - | $3.01 B(+3.7%) |
| Jun 2021 | - | $2.90 B(+37.9%) |
| Mar 2021 | $2.10 B(+7.4%) | $2.10 B(-33.6%) |
| Dec 2020 | - | $3.17 B(+22.8%) |
| Sep 2020 | - | $2.58 B(-4.1%) |
| Jun 2020 | - | $2.69 B(+37.5%) |
| Mar 2020 | $1.96 B(+2.2%) | $1.96 B(-28.9%) |
| Dec 2019 | - | $2.75 B(+6.0%) |
| Sep 2019 | - | $2.60 B(+0.5%) |
| Jun 2019 | - | $2.58 B(+35.0%) |
| Mar 2019 | $1.92 B(+52.2%) | $1.92 B(-15.0%) |
| Dec 2018 | - | $2.25 B(+13.5%) |
| Sep 2018 | - | $1.99 B(-2.7%) |
| Jun 2018 | - | $2.04 B(+62.2%) |
| Mar 2018 | $1.26 B(-41.5%) | $1.26 B(-36.5%) |
| Dec 2017 | - | $1.98 B(+6.3%) |
| Sep 2017 | - | $1.86 B(-4.9%) |
| Jun 2017 | - | $1.96 B(-8.9%) |
| Mar 2017 | $2.15 B(+26.6%) | $2.15 B(+8.0%) |
| Dec 2016 | - | $1.99 B(+2.5%) |
| Sep 2016 | - | $1.94 B(+5.1%) |
| Jun 2016 | - | $1.85 B(+8.9%) |
| Mar 2016 | $1.70 B | $1.70 B(+20.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | - | $1.41 B(+7.6%) |
| Sep 2015 | - | $1.32 B(-6.7%) |
| Jun 2015 | - | $1.41 B(-1.0%) |
| Mar 2015 | $1.42 B(-20.8%) | $1.42 B(+0.9%) |
| Dec 2014 | - | $1.41 B(-0.6%) |
| Sep 2014 | - | $1.42 B(-7.0%) |
| Jun 2014 | - | $1.53 B(-15.1%) |
| Mar 2014 | $1.80 B(-0.4%) | $1.80 B(+53.4%) |
| Dec 2013 | - | $1.17 B(+6.2%) |
| Sep 2013 | - | $1.10 B(+2.1%) |
| Jun 2013 | - | $1.08 B(-40.1%) |
| Mar 2013 | $1.80 B(-15.7%) | $1.80 B(+42.8%) |
| Dec 2012 | - | $1.26 B(+0.1%) |
| Sep 2012 | - | $1.26 B(+0.7%) |
| Jun 2012 | - | $1.25 B(-41.4%) |
| Mar 2012 | $2.14 B(+121.6%) | $2.14 B(+69.7%) |
| Dec 2011 | - | $1.26 B(+7.6%) |
| Sep 2011 | - | $1.17 B(+25.0%) |
| Jun 2011 | - | $937.32 M(-2.9%) |
| Mar 2011 | $965.45 M(-53.9%) | $965.45 M(-4.8%) |
| Dec 2010 | - | $1.01 B(+12.8%) |
| Sep 2010 | - | $899.30 M(+8.3%) |
| Jun 2010 | - | $830.46 M(-60.3%) |
| Mar 2010 | $2.09 B(-13.2%) | $2.09 B(+161.0%) |
| Dec 2009 | - | $802.41 M(-0.9%) |
| Sep 2009 | - | $809.63 M(-66.4%) |
| Mar 2009 | $2.41 B(+232.5%) | $2.41 B(+190.0%) |
| Dec 2008 | - | $831.72 M |
| Mar 2008 | $725.37 M(+55.0%) | - |
| Mar 2007 | $467.98 M(+8.7%) | - |
| Mar 2006 | $430.60 M(+0.9%) | - |
| Mar 2005 | $426.71 M(-15.5%) | - |
| Mar 2004 | $505.15 M(+9.6%) | - |
| Mar 2003 | $461.04 M(+7.6%) | - |
| Mar 2002 | $428.47 M(-40.7%) | - |
| Mar 2001 | $722.26 M | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual accounts payable?
- What is the all time high annual accounts payable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual accounts payable year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly accounts payable?
- What is the all time high quarterly accounts payable for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly accounts payable year-on-year change?
What is Takeda Pharmaceutical Company Limited annual accounts payable?
The current annual accounts payable of TAK is $2.11 B
What is the all time high annual accounts payable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual accounts payable is $2.42 B
What is Takeda Pharmaceutical Company Limited annual accounts payable year-on-year change?
Over the past year, TAK annual accounts payable has changed by -$193.49 M (-8.39%)
What is Takeda Pharmaceutical Company Limited quarterly accounts payable?
The current quarterly accounts payable of TAK is $2.93 B
What is the all time high quarterly accounts payable for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly accounts payable is $3.43 B
What is Takeda Pharmaceutical Company Limited quarterly accounts payable year-on-year change?
Over the past year, TAK quarterly accounts payable has changed by +$36.26 M (+1.25%)